Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT05302024 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Iguratimod

Sponsor

Peking University People's Hospital